Diagnostic laboratory for bleeding disorders ensures efficient management of haemorrhagic disorders

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia Vol. 22; no. S5; pp. 90 - 95
• Main Authors: Riddell, A., Chuansumrit, A., El-Ekiaby, M., Nair, S. C.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.07.2016
• Subjects: Blood Coagulation Disorders - diagnosis; Blood Coagulation Disorders - drug therapy; blood products quality; coagulation laboratory; Disease Management; Factor VIIa - therapeutic use; Female; haemorrhagic disorders; Hemorrhagic Disorders - diagnosis; Hemorrhagic Disorders - prevention & control; Humans; Laboratories - standards; Postpartum Hemorrhage - prevention & control; Pregnancy; Recombinant Proteins - therapeutic use; Severe Dengue - drug therapy; blood products quality; haemorrhagic disorders; coagulation laboratory
• ISSN: 1351-8216; 1365-2516
• DOI: 10.1111/hae.12988

Haemorrhagic disorders like Postpartum haemorrhage and Dengue haemorrhagic fever are life threatening and requires an active and efficient transfusion service that could provide the most appropriate blood product which could be effective in managing them. This would essentially require prompt identification of the coagulopathy so that the best available product can be given to the bleeding patient to correct the identified haemostatic defect which will help control the bleeding. This would only be possible if the transfusion service has a laboratory to correctly detect the haemostatic defect and that too with an accuracy and precision which is ensured by a good laboratory quality assurance practices. These same processes are necessary for the transfusion services to ensure the quality of the blood products manufactured by them and that it contains adequate amounts of haemostasis factors which will be good to be effective in the management of haemorrhagic disorders. These issues are discussed in detail individually in the management of postpartum haemorrhage and Dengue haemorrhagic fever including when these can help in the use of rFVIIa in Dengue haemorrhagic fever. The requirements to ensure good‐quality blood products are made available for the management of these disorders and the same have also been described.